In VHL-negative xenograft models, treatment with the VEGFR-selective inhibitor axitinib reduces tumor growth and prolongs survival, whereas treatment with crizotinib, which inhibits MET but not VEGFR, is much less effective. This evidence concerns the gene MET and neoplasm.